Updates are available Correction dated 2025-07-10
Click to view Correction: https://doi.org/10.1007/s40120-025-00797-9
-
Authors
Odin, Per
Tærud, Christoffer https://orcid.org/0009-0004-5146-788X
Samuelsson, Jenny
Sabelström, Emma
Lagerlund, Jeanette
Freilich, Jonatan
Stelmaszuk, M. Natalia
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 4 March 2025
Accepted: 1 May 2025
First Online: 10 June 2025
Change Date: 11 July 2025
Change Type: Update
Change Details: The original online version of this article was revised to correct a sentence in the Abstract section.
Change Date: 10 July 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40120-025-00797-9
Declarations
:
: Per Odin has received honoraria for consultation and lectures from AbbVie, Bial, Britannia, Ever, Nordic Infucare, Stada, and Zambon. Christoffer Tærud, Jenny Samuelsson, Emma Sabelström, and Jeanette Lagerlund are employees of AbbVie and hold AbbVie stock. Jonatan Freilich and M. Natalia Stelmaszuk are employees of Parexel and were commissioned by AbbVie to conduct the study. Following the submission of the manuscript, Jonatan Freilich’s affiliation changed to UCB Biopharma, Brussels, Belgium.
: Ethical approval was obtained from the Swedish Ethical Review Authority before commencing the study. Permission to use registry data was obtained from the Swedish National Patient Register, the Prescribed Drug Register, and the Cause of Death Register. This study was conducted in accordance with the Good Clinical Practice Guidelines and all applicable laws and regulations. This study used real-world anonymized data from three national administrative registries, therefore, patient consent was not required for this study.
